Mechanism
How Does Tirzepatide Work?
Tirzepatide activates GIP and GLP-1 receptors simultaneously. Together these slow gastric emptying, increase satiety signalling in the brain, and enhance glucose-dependent insulin release while suppressing inappropriate glucagon. The result is reduced appetite, earlier fullness, and improved glucose handling — effects that persist only while the drug is present.
Key takeaways
- Tirzepatide activates two incretin receptors — GIP and GLP-1 — rather than one.
- Slowed gastric emptying and central satiety signalling reduce food intake.
- Insulin release is glucose-dependent, which is why hypoglycaemia is uncommon on its own.
- The dual mechanism is the leading explanation for larger weight effects than single agonists.
- Effects are present only while the drug is in the system — hence regain after stopping.
| Receptors targeted | GIP and GLP-1 |
|---|---|
| Primary appetite effect | Increased satiety, slowed gastric emptying |
| Insulin effect | Glucose-dependent release |
| Glucagon effect | Suppression of inappropriate secretion |
| Half-life | Approximately five days, supporting weekly dosing |
| Duration of effect | Present only while the drug is being taken |
What do GIP and GLP-1 actually do?
Both are incretin hormones released by the gut after eating. GLP-1 slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin secretion, and suppresses glucagon. GIP also promotes insulin secretion and appears to influence fat metabolism and the brain's appetite circuitry, though its role is less completely mapped than GLP-1's.
Activating both produces greater effect than activating GLP-1 alone. Some evidence also suggests GIP activity may moderate nausea signalling, which would help explain why the head-to-head trial recorded lower gastrointestinal discontinuation than semaglutide.
Why is hypoglycaemia uncommon with tirzepatide alone?
Because insulin release triggered through the incretin pathway is glucose-dependent: it increases when blood glucose is elevated and subsides when glucose falls. This is fundamentally different from insulin or sulfonylureas, which drive insulin regardless of glucose level and therefore carry meaningful hypoglycaemia risk.
Risk rises when tirzepatide is combined with insulin or a sulfonylurea, which is why prescribers often adjust those medications when starting it.
Why does weight return when treatment stops?
Because the mechanism is pharmacological rather than educational. While tirzepatide is present, appetite signalling is suppressed and gastric emptying is slowed. Remove the drug and those systems return to baseline, appetite increases, and intake rises. SURMOUNT-4 demonstrated exactly this in a randomised withdrawal design.
This is why describing regain as relapse or lack of discipline misrepresents what the evidence shows.
What the evidence shows
- Dual GIP/GLP-1 receptor activation with characterised metabolic effects.
- Glucose-dependent insulin release, limiting hypoglycaemia risk in monotherapy.
- Effects that depend on continued presence of the drug.
What the evidence does not show
- That the mechanism produces identical effects at doses below the studied range.
- That mechanism alone predicts an individual's response.
- That a compounded preparation delivers the same exposure.
Related: Complete guide · Trial evidence
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What happens in the first hours and days after a dose?
After a subcutaneous injection, tirzepatide is absorbed over hours and reaches peak concentration over approximately the following day. Because its half-life is roughly five days, a single dose does not clear before the next is due, which is what produces the relatively stable exposure that weekly dosing is designed to achieve. It also means that a dose taken today is acting on a body that still contains a substantial fraction of the previous several doses.
This accumulation explains a pattern many people notice: effects intensify over the first month at a given dose rather than appearing fully after the first injection. Steady state — the point at which the amount entering equals the amount clearing — takes roughly four to five weeks at each dose level. Judging a dose before that point measures an incomplete exposure.
Why does slowed gastric emptying matter beyond fullness?
Delayed gastric emptying is the mechanism behind the sensation of prolonged fullness, but it has consequences well beyond appetite. It is the reason nausea concentrates around dose increases, because the stomach is adapting to a new rate. It is the reason anaesthesia teams have issued specific guidance, because standard preoperative fasting assumes a predictable emptying rate that no longer holds. And it is the reason labelling addresses oral contraceptive absorption specifically.
It is worth understanding that these are not separate side effects to be memorised but a single pharmacological property producing different consequences in different contexts. A person who understands the mechanism can anticipate which situations warrant a conversation with a clinician, rather than treating each as an unrelated warning.
What is glucose-dependent insulin release, and why does it reduce risk?
Insulin secretion driven through the incretin pathway rises when blood glucose is elevated and subsides when it falls. This dependency is a safety feature: it means the drug does not push glucose down indefinitely the way insulin or a sulfonylurea can, which is why hypoglycaemia is uncommon with tirzepatide used alone.
The qualifier matters enormously. When tirzepatide is added to insulin or a sulfonylurea, those agents continue driving insulin regardless of glucose level, and the combination of their action with reduced food intake can produce hypoglycaemia. This is why prescribers commonly review and adjust those medications when starting tirzepatide, and why anyone taking them should treat the addition as a change requiring monitoring rather than a simple add-on.
What does this page cover, and what does it deliberately leave out?
This page addresses GIP and GLP-1 activity, appetite and gastric emptying and glucose, organised around the primary question of how tirzepatide works. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Gip and glp-1 activity | Covered on this page | Primary evidence |
| Appetite | Covered on this page | Primary evidence |
| Gastric emptying and glucose | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on how tirzepatide works.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 12 technical terms this page uses, including GIP, GLP-1, compounded, gastric emptying — in the specific sense used above.
| GIP | Glucose-dependent insulinotropic polypeptide. An incretin hormone released by the small intestine after eating. Tirzepatide activates its receptor alongside the GLP-1 receptor, which is the feature that distinguishes it from single-agonist drugs such as semaglutide. |
|---|---|
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| gastric emptying | The rate at which food leaves the stomach. Incretin therapies slow it, which prolongs fullness and is also the mechanism behind much of the nausea and the perioperative aspiration concern. |
| half-life | The time taken for the amount of drug in the body to fall by half. Tirzepatide's is roughly five days, which supports once-weekly dosing and means steady state takes several weeks. |
| hypoglycaemia | Abnormally low blood glucose. Uncommon with tirzepatide alone because its insulin effect is glucose-dependent, but meaningfully more likely when combined with insulin or a sulfonylurea. |
| incretin | A gut hormone released in response to food that amplifies insulin secretion. GIP and GLP-1 are the two principal human incretins, and the drug class that mimics them is named after them. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| randomised withdrawal | A design in which everyone first receives the active drug, and only those who respond are then randomised to continue or stop. SURMOUNT-4 used this design, which is why its regain finding cannot be explained away by differences between groups. |
| steady state | The point at which the amount of drug entering the body equals the amount being cleared, so exposure stops rising. It takes roughly four to five weeks at a given tirzepatide dose. |
| subcutaneous | Beneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. |
| sulfonylurea | A class of oral diabetes medication that stimulates insulin release regardless of glucose level, which is why combining it with tirzepatide raises hypoglycaemia risk. |
Frequently asked questions
How does tirzepatide differ from semaglutide mechanistically?
Semaglutide activates the GLP-1 receptor only; tirzepatide activates both GIP and GLP-1 receptors.
Does tirzepatide cause low blood sugar?
Uncommonly on its own, because insulin release is glucose-dependent. Risk increases when combined with insulin or a sulfonylurea.
Why is it injected weekly?
Its half-life of roughly five days supports once-weekly dosing.
Does it speed up metabolism?
The dominant effect is reduced energy intake through appetite suppression and slowed gastric emptying, not a large increase in energy expenditure.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.